KLHDC4 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the well-characterized HeLa cervical adenocarcinoma cell line, engineered to disrupt the KLHDC4 gene. This polyclonal knockout product provides a heterogeneous mixture of cells carrying various loss-of-function mutations in the target gene, enabling functional studies without clonal selection bias. As a loss-of-function model, it serves as a valuable tool for dissecting the roles of KLHDC4 in cellular processes such as protein degradation and apoptosis.
The HeLa host cell line is an immortalized human cell line established from cervical carcinoma tissue of Henrietta Lacks in 1951 and has since become one of the most widely used models in biomedical research. HeLa cells exhibit robust growth characteristics, are amenable to genetic manipulation, and are extensively utilized in cancer biology, virology, and drug discovery. Their origin from a cervical adenocarcinoma makes them particularly relevant for studying cervical cancer biology and oncogenic signaling pathways.
KLHDC4 encodes a kelch-repeat-containing protein that is predicted to function as a substrate adaptor for Cullin-RING E3 ubiquitin ligase complexes, particularly interacting with Cullin-2 (CUL2) and Cullin-3 (CUL3). Within the ubiquitin-proteasome system, KLHDC4 is believed to recruit specific substrates for ubiquitination, subsequently targeting them for proteasomal degradation. Through this mechanism, KLHDC4 potentially modulates key cellular processes including apoptosis and cell cycle regulation, although its precise substrates remain uncharacterized. The Cullin-RING E3 ligases, ubiquitin, and the proteasome constitute the core molecular machinery linked to its function.
In the context of HeLa cells, disruption of KLHDC4 allows researchers to investigate how alterations in ubiquitin-mediated proteolysis influence cervical cancer cell behavior. Given its putative role in apoptosis and cell proliferation, this knockout model is a relevant system for examining the contribution of KLHDC4 to oncogenic phenotypes and may aid in target validation efforts for cancer therapy. The polyclonal nature of the knockout population reflects the diversity of editing outcomes and can more closely mirror the heterogeneity found in tumor cell populations.
Typical applications include Western blotting and RT-qPCR to confirm KLHDC4 expression changes, cell viability and apoptosis assays to assess functional impact, co-immunoprecipitation and ubiquitination assays to probe protein interactions and E3 ligase activity, and flow cytometry for cell cycle analysis. This product is suited for both hypothesis-driven mechanistic studies and broader phenotypic screens in cancer cell biology. Researchers can utilize these polyclonal knockout cells to dissect the ubiquitin-proteasome pathway and its intersection with cervical cancer pathology. For additional details and ordering information, please contact Ascent Research.
